Healthy Volunteer
Conditions
Brief summary
The primary objectives of this study were: * To assess the effect of a high-fat diet on the pharmacokinetics (PK) of a 0.75 mg single dose of S-888711 orally administered as 0.25 mg tablets in healthy volunteer adults * To assess the effect of a calcium supplement on the PK of a 0.75 mg single dose of S-888711 orally administered as 0.25 mg tablets in healthy volunteer adults
Interventions
DRUGS-888711
Administered orally as three 0.25 mg tablets
DIETARY_SUPPLEMENTCalcium Antacid
Calcium carbonate 4000 mg chewable tablets
Sponsors
Shionogi
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. A signed and dated written informed consent obtained prior to Screening. 2. Males and females ≥ 18 and ≤ 70 years of age, inclusive (at the time of informed consent). 3. Judged healthy at screening examination by the investigator. 4. Body mass index (BMI) of ≥ 19 to ≤ 29.9 kg/m². 5. All subjects must have agreed to use 2 forms of barrier contraception if engaging in sexual intercourse for at least 7 days prior to the first dose of study drug and continuing throughout the study, excluding subjects who had been surgically sterilized or females who had been postmenopausal (confirmed by follicle stimulating hormone test levels) for at least 1 year. 6. All female subjects must have had a negative urine pregnancy test. 7. Platelet count of 100,000 to 325,000/μL. 8. Willing to submit to blood sampling for the planned PK analysis.
Exclusion criteria
1. The use of prescription or non-prescription drugs, including herbal medicine or dietary supplements, within 14 days prior to dosing, with the exception of up to 3 doses of acetaminophen ≤ 1 gram each permitted from 14 days prior to the first study drug dose through 72 hours prior to the first study drug dose. 2. A history of regular use of tobacco- or nicotine-containing products within 6 months prior to Screening as confirmed by a urine cotinine test. 3. A history of use of inhibitors or inducers of cytochrome P450 (CYP) 3A4 within 14 days prior to Screening. 4. A history of use of platelet aggregation inhibitors, coronary artery vasodilators, calcium antagonists, beta blockers, diuretics, psychotropic drugs, prostaglandins, antibiotics, anticoagulants, and anticlotting or antiplatelet drugs (including aspirin and non-steroidal anti-inflammatory drugs) within 4 weeks prior to Screening. 5. History of use of thrombocytopenia-inducing drugs (eg, quinidine, trimethoprim sulfamethoxazole, etc.) within 4 weeks prior to Screening. 6. Family history of a hematologic disorder. 7. Hemorrhagic tendency. 8. A history of cardiac episode(s) or abnormal finding on electrocardiogram (ECG) and judged as ineligible by the investigator. 9. Chronic disease requiring medication and/or other treatment such as dietary restriction and physical therapy. 10. A history of anaphylaxis or significant side effect induced by a drug. 11. A history of allergic symptoms including food allergy, but excluding inactive pollen allergy. 12. A history of abuse of alcohol and/or drugs. 13. Positive urine screen for drug abuse. 14. A history of gastrointestinal surgery making subject ineligible as judged by the investigator. 15. Judged ineligible for this study by the investigator due to a history or clinical manifestations of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, or urological disease or other clinically important disorder. 16. Positive laboratory results for hepatitis A IgM antibody, hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus at Screening. 17. Donation of \>400 mL of blood within 12 weeks or \>200 mL of blood within 4 weeks prior to Screening. 18. Prior administration of S-888711. 19. Use of other investigational products within 30 days or 6 half-lives (whichever was longer) prior to the first dose of study medication. 20. Judged ineligible for this study by the investigator for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under the Concentration-time Curve from Time Zero to the Time Point of the Last Quantifiable Concentration of S-888711 | Predose and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours after dosing |
| Maximum Observed Plasma Concentration of S-888711 | Predose and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours after dosing |
| Time to Maximum Observed Plasma Concentration of S-888711 | Predose and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours after dosing |
| Apparent Total Clearance of S-888711 | Predose and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours after dosing |
| Area Under the Concentration-time Curve from Time Zero to Infinity of S-888711 | Predose and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours after dosing |
| Terminal Elimination Half-life of S-888711 | Predose and 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours after dosing |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants with Treatment-emergent Adverse Events | up to 40 days |
Countries
United States
Outcome results
None listed